Announcements Trials
Browse Landscape

Phase

Phase 2 88Phase 1 67Phase 1/2 41Phase NA 18Phase 3 11Phase 2/3 3Phase EARLY_PHASE1 1

Status

Completed 8Unknown 3Terminated 3Recruiting 3Active not recruiting 2

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 3Myeloid 3Lymphoid 2Plasma cell 1

Conditions

Breast Neoplasms 13Neoplasms 10Carcinoma, Non-Small-Cell Lung 10Lung Neoplasms 9Recurrence 6Prostatic Neoplasms 6Neoplasm Metastasis 6Head and Neck Neoplasms 6Carcinoma, Hepatocellular 6Stomach Neoplasms 5Pancreatic Neoplasms 5Colorectal Neoplasms 5Carcinoma, Squamous Cell 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Multiple Myeloma 4Melanoma 4Liver Neoplasms 4Ovarian Neoplasms 3Myelodysplastic Syndromes 3Lymphoma, Non-Hodgkin 3Lymphoma, Large B-Cell, Diffuse 3Hematologic Neoplasms 3Fatigue 3Esophageal Neoplasms 3Endometrial Neoplasms 3Depression 3Urinary Bladder Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Sarcoma 2Rectal Neoplasms 2

Interventions

Gemtuzumab 1Cyclophosphamide 1AP 1903 reagent 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2/3 × Terminated × Myelodysplastic Syndromes × Clear all
NCT03699475 2023-09-29

THRIVE

Bellicum Pharmaceuticals

Phase 2/3 Terminated
1 enrolled 9 charts
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT00967343 2021-06-14

Efficacy and Safety of a Donor Lymphocyte Preparation Depleted of Functional Host Alloreactive T-cells (ATIR) in Patients Undergoing a Peripheral Blood Stem Cell Transplant From a Related, Haploidentical Donor

Kiadis Pharma

Phase 2/3 Terminated
40 enrolled 10 charts
LymphoidMyeloidOther hematologic neoplasmPlasma cell

Graft vs Host Disease, Leukemia, Myeloid, Lymphoma, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT00038805 2018-10-31

Nonmyeloablative Preparative Regimen Using Mylotarg for Patients With High Risk Acute Myeloid Leukemia (AML), Acute Lymphocytic Leukemia (ALL), Chronic Myeloid Leukemia (CML) and Myelodysplastic Syndrome (MDS)

M.D. Anderson Cancer Center

Phase 2/3 Terminated
3 enrolled
LymphoidMyeloidOther hematologic neoplasm

Leukemia, Myelodysplastic Syndromes, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡